Anchor Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Anchor Therapeutics's estimated annual revenue is currently $1.1M per year.
- Anchor Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Anchor Therapeutics has 7 Employees.
- Anchor Therapeutics grew their employee count by 0% last year.
Anchor Therapeutics's People
| Name | Title | Email/Phone |
|---|
Anchor Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Anchor Therapeutics?
Anchor Therapeutics is pioneering a new class of drugs called Pepducins. Pepducins are a breakthrough approach to targeting and allosterically modulating G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane. GPCRs are critically involved in a wide variety of serious illnesses, including diabetes, inflammation, cancer, CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets including orphan and intractable targets.
keywords:N/A
N/A
Total Funding
7
Number of Employees
$1.1M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.5M | 7 | -53% | $7.9M |
#2 | $0.5M | 7 | -42% | $132.1M |
#3 | $0.1M | 7 | 0% | $24M |
#4 | $0.1M | 7 | -78% | $21.8M |
#5 | $0.5M | 7 | -36% | N/A |